Personalis, Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Tempus AI agreed to acquire Personalis Inc. for $16.25 per share in an all-stock transaction (with option for up to 50% cash), valuing the company at $1.5B net of Tempus' existing stake. Personalis shareholders will receive a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share. Closing expected late 2026/early 2027, subject to shareholder approval and regulatory clearance. Transaction builds on existing November 2023 partnership where Tempus invested and began commercializing Personalis' NeXT Personal MRD test.
Why this rating
Acquisition at 260% of $578M market cap materially changes Personalis trajectory—transforms independent biotech to Tempus subsidiary, eliminating public company status; validates MRD technology value; implies confidence in $20B MRD market opportunity.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.